Sutro Biopharma (STRO) Non-Current Deffered Revenue (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Non-Current Deffered Revenue data on file, last reported at $2.0 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Deffered Revenue fell 83.82% year-over-year to $2.0 million; the trailing twelve-month figure through Dec 2025 stood at $2.0 million (down 83.82% YoY), and the FY2025 full-year result was $2.0 million, down 83.82% from the prior year.
• Non-Current Deffered Revenue fell to $2.0 million in Q4 2025, from $3.8 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $90.0 million in Q2 2022 to a low of $145000.0 in Q3 2021.
• A 5-year average of $37.5 million and a median of $19.8 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue slumped 98.27% in 2021 and jumped 51439.31% in 2022, its largest moves.
• Tracing STRO's Non-Current Deffered Revenue over 5 years: stood at $145000.0 in 2021, then jumped by 61889.66% to $89.9 million in 2022, then slumped by 40.61% to $53.4 million in 2023, then slumped by 76.52% to $12.5 million in 2024, then tumbled by 83.82% to $2.0 million in 2025.
• Business Quant data shows STRO's Non-Current Deffered Revenue at $2.0 million in Q4 2025, $3.8 million in Q3 2025, and $6.9 million in Q2 2025.